<DOC>
	<DOC>NCT02651363</DOC>
	<brief_summary>The purpose of this study is to collect adverse events and identify risk factors in patients that are taking Dolocordralan Extra 25® and Dolocordralan Extra Forte®</brief_summary>
	<brief_title>Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With Pain</brief_title>
	<detailed_description />
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Patients who are prescribed Dolocordralan Extra 25 and Dolocordralan Extra Forte at any of the participating clinics Patients who sign the informed consent form Patients who agree to comply with the study procedures Please see the protocol for further information on exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>